A novel amino acid formulation that improves iron absorption and corrects gastrointestinal motility alterations caused by iron deficiency and supplementation, enhancing iron bioavailability and reducing mucosal damage.
This innovative solution addresses the common problem of iron deficiency and the adverse effects of iron supplementation on gastrointestinal motility. The novel amino acid formulation effectively enhances iron bioavailability by upregulating DMT1 expression, which aids in iron absorption. It also mitigates the negative impacts of excess iron, such as motility disruptions and mucosal damage, by restoring normal muscle contraction and prolonging intestinal transit time.
Key features:
Applications:
Currently at TRL 4, this formulation has been validated in laboratory settings with both in vitro and in vivo studies. It has demonstrated effectiveness in improving hemoglobin levels and correcting motility abnormalities in animal models, indicating promising potential for further development and clinical application.
The University of Florida is a comprehensive public research university with a broad academic and research portfolio and a statewide presence. Industry collaborates through co-located labs and shared core facilities and through an integrated academic health system that accelerates clinical translation. A statewide extension network and multiple research and education sites connect companies with field-scale testing and rapid deployment, while incubators and an adjacent innovation district provide pathways from lab to market. Research is supported by competitive funding from major federal agencies such as NIH, NSF, USDA, and DOE. A dedicated technology transfer office supports IP, licensing, and startup formation.